GDF-8 / Myostatin Inhibitors
Myostatin Inhibitorclinical_trialsAlso known as: Myostatin Inhibitors, GDF-8 Antibodies, Stamulumab, Domagrozumab, Bimagrumab, Anti-Myostatin Therapies
A class of biological agents that block myostatin (GDF-8), the body's primary muscle growth inhibitor, enabling significant increases in muscle mass — the 'holy grail' of muscle-building therapeutics.
Overview
GDF-8 (Growth Differentiation Factor 8), commonly known as myostatin, is a protein produced by muscle cells that acts as a negative regulator of muscle growth. When myostatin is blocked or absent, dramatic muscle hypertrophy occurs — as seen in 'double-muscled' cattle breeds (Belgian Blue) and the famous case of a German child born with a myostatin mutation who showed extraordinary muscle development. Multiple pharmaceutical approaches to myostatin inhibition have been developed: (1) Anti-myostatin antibodies (Stamulumab/MYO-029, Domagrozumab); (2) ActRIIB receptor blockers (ACE-031, Bimagrumab); (3) Follistatin and its analogs; (4) Propeptide-based inhibitors. While clinical trials for muscular dystrophy and sarcopenia have shown proof of concept, results have been mixed, with some programs discontinued due to limited efficacy or side effects. The concept remains enormously popular in bodybuilding and performance communities.
Mechanism of Action
Myostatin inhibition removes the natural brake on muscle growth: (1) Myostatin normally binds ActRIIB receptors, activating SMAD2/3 to suppress myogenesis; (2) Blocking myostatin prevents this signaling, unleashing muscle growth pathways; (3) Satellite cells proliferate and differentiate more readily; (4) Akt/mTOR pathway is disinhibited, increasing protein synthesis; (5) Multiple approaches exist — antibodies bind myostatin directly, decoy receptors trap it, follistatin sequesters it; (6) Effects include both hypertrophy (larger fibers) and hyperplasia (more fibers); (7) Secondary effects may include reduced fat mass through improved metabolic rate.
Molecular Formula
Varies by agent (antibodies, proteins, peptides)
Molecular Weight
Varies — antibodies ~150,000 g/mol; peptide inhibitors vary
Sequence
Various — class includes antibodies, fusion proteins, and peptide-based inhibitors
Dosage Protocols
Dose Range
Varies by agent – Varies by agent
Frequency
Bimagrumab: monthly IV; Domagrozumab: every 4 weeks IV
Route
intravenous or subcutaneous (depending on agent)
Cycle Length
As per clinical trial protocols
No established protocols for performance use. Clinical trial dosing for reference only. These are biological agents requiring medical administration and monitoring.
Source: Various Phase 2/3 clinical trials
🧮 Personalized Dosage Calculator
💰 Estimated Pricing
Typical Supply
1mg vial
Last Updated
2026-02
Myostatin (GDF-8) inhibitors. Research-only. Includes various experimental compounds. Limited availability.
⚠️ Prices are estimates based on publicly available data and may vary significantly by vendor, location, and prescription status. This is not medical or financial advice.
Side Effects
| Effect | Severity |
|---|---|
| Muscle cramping | mild |
| Diarrhea | mild |
| Epistaxis | moderate |
| Injection/infusion reactions | mild |
| Joint pain | mild |
Pros & Cons
Targets the fundamental biological limit on muscle growth
Dramatic proof-of-concept from genetic knockouts showing 2-3x normal muscle mass
Multiple clinical programs validating the approach in humans
Bimagrumab showed significant fat loss alongside muscle gain in clinical trials
No approved agents available for performance use
Clinical trial results have been disappointing for functional improvements despite mass gains
Off-target effects from blocking related TGF-beta ligands (BMP-9/10) cause vascular issues
Antibody-based agents require IV infusion and are practically unobtainable
Long-term safety of chronic myostatin inhibition remains unknown
Research Studies
🩸 Blood Work
No specific bloodwork requirements reported for this peptide. General health panels are always recommended before starting any peptide protocol.
Legal Status
All agents investigational and not approved for muscle building. Clinical trials ongoing for muscular dystrophy, sarcopenia, and cachexia. Banned by WADA. Not legally available for performance enhancement.
Readers Also Viewed
Semaglutide
99An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management, producing significant weight loss of 15-17% body weight in clinical trials.
BPC-157
98A 15-amino acid synthetic peptide derived from human gastric juice that promotes healing of tendons, ligaments, muscles, gut lining, and other tissues through multiple regenerative pathways.
Tirzepatide
97A first-in-class dual GIP/GLP-1 receptor agonist that produces up to 22.5% body weight loss, approved for type 2 diabetes and obesity management.
CJC-1295 + Ipamorelin (Combo)
95The most popular growth hormone peptide combination, pairing a GHRH analog (CJC-1295) with a ghrelin mimetic (Ipamorelin) for synergistic GH release with minimal side effects.
Related Peptides
Semaglutide
An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management, producing significant weight loss of 15-17% body weight in clinical trials.
BPC-157
A 15-amino acid synthetic peptide derived from human gastric juice that promotes healing of tendons, ligaments, muscles, gut lining, and other tissues through multiple regenerative pathways.
Tirzepatide
A first-in-class dual GIP/GLP-1 receptor agonist that produces up to 22.5% body weight loss, approved for type 2 diabetes and obesity management.
CJC-1295 + Ipamorelin (Combo)
The most popular growth hormone peptide combination, pairing a GHRH analog (CJC-1295) with a ghrelin mimetic (Ipamorelin) for synergistic GH release with minimal side effects.